Beta-2 -microglobulin is a tumor marker for
**Question:** Beta-2 -microglobulin is a tumor marker for
A. Multiple Myeloma
B. Chronic Lymphocytic Leukemia
C. Non-Hodgkin's Lymphoma
D. Chronic Hepatitis
**Core Concept:** Beta-2 -microglobulin is a small protein that is produced by cells involved in the immune response, particularly B cells and plasma cells. It plays a role in the binding of antibodies to antigens and is also a component of HLA-class I molecules.
**Why the Correct Answer is Right:** Beta-2 -microglobulin is an appropriate tumor marker for several types of cancers, particularly B cell malignancies. In this case, the correct answer is Multiple Myeloma (MM) because it is a plasma cell malignancy characterized by the clonal proliferation of plasma cells within the bone marrow. These plasma cells secrete large amounts of monoclonal immunoglobulins, including beta-2 -microglobulin, leading to elevated levels in the blood and urine.
**Why Each Wrong Option is Incorrect:**
A. Multiple myeloma is not the only application of beta-2 -microglobulin as a tumor marker. However, it is one of the most significant applications due to the involvement of plasma cells in the disease.
B. Chronic Lymphocytic Leukemia (CLL) is a lymphoproliferative disorder, but it primarily involves lymphocytes, not plasma cells. Thus, beta-2 -microglobulin is not typically elevated in CLL.
C. Non-Hodgkin's lymphoma (NHL) is another lymphoproliferative disorder, but it is also predominantly related to lymphocytes rather than plasma cells. Therefore, beta-2 -microglobulin is not a reliable tumor marker for NHL.
D. Chronic Hepatitis is an inflammatory liver condition, not a neoplastic disorder involving plasma cells. Consequently, beta-2 -microglobulin is not a reliable tumor marker for Hepatitis.
**Clinical Pearl:** Beta-2 -microglobulin is a useful tumor marker for B cell malignancies, particularly Multiple Myeloma, due to the significant involvement of plasma cells in the disease. Elevated beta-2 -microglobulin levels can aid in diagnosing, monitoring response to treatment, and predicting prognosis in patients with Multiple Myeloma.